NUVL logo

Nuvalent (NUVL) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

29 July 2021

Indexes:

Not included

Description:

Nuvalent (NUVL) is a biotechnology company focused on developing targeted therapies for cancer. They create innovative treatments that aim to improve patient outcomes by specifically targeting cancer cells while minimizing effects on healthy cells. Their research emphasizes precision medicine to address various types of cancer effectively.

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

30 Dec '24 HC Wainwright & Co.
Buy
13 Nov '24 BMO Capital
Outperform
24 Oct '24 UBS
Neutral
04 Oct '24 JP Morgan
Overweight
16 Sept '24 Wedbush
Outperform
16 Sept '24 Stifel
Buy
16 Sept '24 Guggenheim
Buy
16 Sept '24 BMO Capital
Outperform
09 Sept '24 Wedbush
Outperform
04 Sept '24 JP Morgan
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Nuvalent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
NUVL
prnewswire.com19 December 2024

CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company in the clinical stage that aims to develop targeted treatments for confirmed kinase targets in cancer, has announced today that James Porter, Ph.D.

Nuvalent Appoints Grant Bogle to Board of Directors
Nuvalent Appoints Grant Bogle to Board of Directors
Nuvalent Appoints Grant Bogle to Board of Directors
NUVL
prnewswire.com09 December 2024

On December 9, 2024, in Cambridge, Massachusetts, Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company in the clinical stage that develops targeted cancer therapies, announced that Grant Bogle has been appointed to its Board of Directors.

Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
Nuvalent Highlights Corporate and Pipeline Achievements, Reiterates Key Anticipated Milestones, and Reports Third Quarter 2024 Financial Results
NUVL
prnewswire.com12 November 2024

The successful completion of all expected milestones for 2024 and faster development schedules support the OnTarget 2026 plan, aiming for the first approved product by 2026. Dr. Alice Shaw, a prominent medical oncologist, has been appointed to the Scientific Advisory Board. The company has a strong cash reserve of $1.2 billion, which includes funds from a larger public offering of $575 million, and this is projected to sustain operations until 2028.

Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
Nuvalent: Promising Data Keeps Validating Pipeline And Platform
NUVL
seekingalpha.com23 September 2024

Nuvalent's main drug candidates, NVL-520 and NVL-655, have demonstrated good effectiveness and safety in early trials. They have been granted Breakthrough Therapy and orphan drug status by the FDA, with important Phase 2 results anticipated in 2025 and possible approvals by 2026. The company also raised $500 million through a secondary offering, indicating strong interest from investors and ensuring funding for Phase 3 trials.

Nuvalent Announces Closing of Upsized Public Offering of Common Stock
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
Nuvalent Announces Closing of Upsized Public Offering of Common Stock
NUVL
prnewswire.com18 September 2024

On September 18, 2024, Nuvalent, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, announced that it has successfully completed its larger-than-expected public offering of 5,750,000 shares of Class A common stock. This total includes an additional 750,000 shares that the underwriters fully exercised their option to buy. The shares were offered to the public at a price of $100.00 each.

Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
Nuvalent Stock Moves Up 20% in a Week: What's Driving the Rally?
NUVL
zacks.com18 September 2024

The positive news follows NUVL's announcement of promising results from two experimental treatments for lung cancer.

Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
Nuvalent: NSCLC Program Now Lends Credibility Towards 2025 Pivotal Data Releases
NUVL
seekingalpha.com17 September 2024

Nuvalent, Inc. reported encouraging results from the phase 1/2 ALKOVE-1 study, which tested NVL-655 on patients with ALK-mutant non-small cell lung cancer (NSCLC). They also had positive outcomes from the phase 1/2 ARROS-1 study, where zidesamtinib was used for patients with ROS-1 mutant NSCLC. The global market for non-small cell lung cancer is expected to grow to $36.9 billion by 2031, with 3% to 5% of cases being ALK-positive and 1% to 3% being ROS-1 positive.

Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
Nuvalent Announces Pricing of Upsized Public Offering of Common Stock
NUVL
prnewswire.com16 September 2024

On September 16, 2024, Nuvalent, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, announced that it has increased its public offering to sell 5,000,000 shares of Class A common stock. The shares are priced at $100.00 each for the public. The company focuses on developing targeted therapies for specific kinase targets in cancer treatment.

Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
Nuvalent Stock Jumps On ESMO Data Presentation, Seeks To Raise $350M Via Equity
NUVL
benzinga.com16 September 2024

During the weekend, Nuvalent, Inc. (NUVL) showcased new information from the Phase 1 dose-escalation stages of the ongoing ARROS-1 Phase 1/2 trial for zidesamtinib and the ALKOVE-1 Phase 1/2 trial for NVL-655 at the European Society for Medical Oncology (ESMO) Congress 2024.

Cancer Biotech Nuvalent's Stock Jumps on Positive Data
Cancer Biotech Nuvalent's Stock Jumps on Positive Data
Cancer Biotech Nuvalent's Stock Jumps on Positive Data
NUVL
barrons.com16 September 2024

Biotech company Nuvalent shared new information about two experimental cancer drugs over the weekend. Experts believe that both could be the top treatments in their respective categories.

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the primary business of Nuvalent?
  • What is the ticker symbol for Nuvalent?
  • Does Nuvalent pay dividends?
  • What sector is Nuvalent in?
  • What industry is Nuvalent in?
  • What country is Nuvalent based in?
  • When did Nuvalent go public?
  • Is Nuvalent in the S&P 500?
  • Is Nuvalent in the NASDAQ 100?
  • Is Nuvalent in the Dow Jones?
  • When was Nuvalent's last earnings report?
  • When does Nuvalent report earnings?
  • Should I buy Nuvalent stock now?

What is the primary business of Nuvalent?

Nuvalent (NUVL) is a biotechnology company focused on developing targeted therapies for cancer. They create innovative treatments that aim to improve patient outcomes by specifically targeting cancer cells while minimizing effects on healthy cells. Their research emphasizes precision medicine to address various types of cancer effectively.

What is the ticker symbol for Nuvalent?

The ticker symbol for Nuvalent is NASDAQ:NUVL

Does Nuvalent pay dividends?

No, Nuvalent does not pay dividends

What sector is Nuvalent in?

Nuvalent is in the Healthcare sector

What industry is Nuvalent in?

Nuvalent is in the Biotechnology industry

What country is Nuvalent based in?

Nuvalent is headquartered in United States

When did Nuvalent go public?

Nuvalent's initial public offering (IPO) was on 29 July 2021

Is Nuvalent in the S&P 500?

No, Nuvalent is not included in the S&P 500 index

Is Nuvalent in the NASDAQ 100?

No, Nuvalent is not included in the NASDAQ 100 index

Is Nuvalent in the Dow Jones?

No, Nuvalent is not included in the Dow Jones index

When was Nuvalent's last earnings report?

Nuvalent's most recent earnings report was on 12 November 2024

When does Nuvalent report earnings?

The next expected earnings date for Nuvalent is 27 February 2025

Should I buy Nuvalent stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions